Loading…
Lobbying Spend
$760K
Filings
45
Firms Hired
3
Active Period
2017–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2023
2022 · fourth_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Client expense: $130,000 · Firm income: —
Matched citations: H.R. 2617
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Client expense: $130,000 · Firm income: —
Matched citations: H.R 5585
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · fourth_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Client expense: $130,000 · Firm income: —
Matched citations: H.R. 6833
Accelerated Approval Integrity Act of 2022
2022 · fourth_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Client expense: $130,000 · Firm income: —
Matched citations: H.R. 6963
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Next Generation COVID-19 vaccines and boosters; Issues related to ASPR/BARDA and manufacturing of COVID-10 vaccines and boosters; Issues related to Oncology and HPV cancers; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; FY2023 Omnibus Appropriations Act, H.R. 2617; Issues related to the Prescription Drug User Fee Act (PDUFA); Issues related to the Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness
Client expense: $130,000 · Firm income: —
Matched citations: S. 3799
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Client expense: $140,000 · Firm income: —
Matched citations: H.R 5585
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 6833
Accelerated Approval Integrity Act of 2022
2022 · third_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 6963
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.
Client expense: $140,000 · Firm income: —
Matched citations: S. 3799
Speeding Therapy Access Today Act of 2021
2022 · second_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 1730
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Client expense: $140,000 · Firm income: —
Matched citations: H.R 5585
Accelerated Approval Integrity Act of 2022
2022 · second_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Client expense: $140,000 · Firm income: —
Matched citations: H.R. 6963
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
Client expense: $140,000 · Firm income: —
Matched citations: S. 3799
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
Client expense: $150,000 · Firm income: —
Matched citations: H.R. 6000
Accelerated Approval Integrity Act of 2022
2022 · first_quarter · Firm: INOVIO PHARMACEUTICALS
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
Client expense: $150,000 · Firm income: —
Matched citations: H.R. 6963
COVID Supplemental Appropriations Act, 2022
2022 · first_quarter · Firm: INOVIO PHARMACEUTICALS
COVID-19 Supplemental Appropriations Act of 2022, H.R. 7007, AG/FDA FY2023 appropriations, State, Foreign Ops FY2023 appropriations; LHHS FY2023 appropriations
Client expense: $150,000 · Firm income: —
Matched citations: H.R. 7007
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology Next Generation COVID-19 vaccines; Medicare Part B and HPV; Orphan Drug Act of 1983 Orphan Drug Tax Credit - The Build Back Better Act, H.R. 5673; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendments (MDUFA IV); Prevent Pandemics Act, S. 3799; Cures 2.0, H.R. 6000; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and therapies TRIPS Waiver for COVID-19 vaccines and therapies; Outreach to Colombian Congressional Caucus on COVID-19
Client expense: $150,000 · Firm income: —
Matched citations: S. 3799
Source: Senate LDA